BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 37109105)

  • 1. Protein Induced by Vitamin K Absence II: A Potential Biomarker to Differentiate Pancreatic Ductal Adenocarcinoma from Pancreatic Benign Lesions and Predict Vascular Invasion.
    Yang Y; Li G; Zhang Y; Cui Y; Liu J
    J Clin Med; 2023 Apr; 12(8):. PubMed ID: 37109105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PIVKA-II: A biomarker for diagnosing and monitoring patients with pancreatic adenocarcinoma.
    Tartaglione S; Mancini P; Viggiani V; Chirletti P; Angeloni A; Anastasi E
    PLoS One; 2021; 16(5):e0251656. PubMed ID: 34015010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic value of serum PIVKA-II levels for BCLC early hepatocellular carcinoma and correlation with HBV DNA.
    Wu J; Xiang Z; Bai L; He L; Tan L; Hu M; Ren Y
    Cancer Biomark; 2018; 23(2):235-242. PubMed ID: 30103302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein Induced by Vitamin K Absence II (PIVKA-II) as a potential serological biomarker in pancreatic cancer: a pilot study.
    Tartaglione S; Pecorella I; Zarrillo SR; Granato T; Viggiani V; Manganaro L; Marchese C; Angeloni A; Anastasi E
    Biochem Med (Zagreb); 2019 Jun; 29(2):020707. PubMed ID: 31223261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Performance of PIVKA-II for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion.
    Poté N; Cauchy F; Albuquerque M; Voitot H; Belghiti J; Castera L; Puy H; Bedossa P; Paradis V
    J Hepatol; 2015 Apr; 62(4):848-54. PubMed ID: 25450201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma.
    Feng H; Li B; Li Z; Wei Q; Ren L
    BMC Cancer; 2021 Apr; 21(1):401. PubMed ID: 33849479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Value of AFP and PIVKA-II in diagnosis of HBV-related hepatocellular carcinoma and prediction of vascular invasion and tumor differentiation.
    Si YQ; Wang XQ; Fan G; Wang CY; Zheng YW; Song X; Pan CC; Chu FL; Liu ZF; Lu BR; Lu ZM
    Infect Agent Cancer; 2020 Nov; 15(1):70. PubMed ID: 33292429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PANC-1 Cell Line as an Experimental Model for Characterizing PIVKA-II Production, Distribution, and Molecular Mechanisms Leading to Protein Release in PDAC.
    Farina A; Tartaglione S; Preziosi A; Mancini P; Angeloni A; Anastasi E
    Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of four candidate pancreatic cancer serological biomarkers that improve the performance of CA19.9.
    Makawita S; Dimitromanolakis A; Soosaipillai A; Soleas I; Chan A; Gallinger S; Haun RS; Blasutig IM; Diamandis EP
    BMC Cancer; 2013 Sep; 13():404. PubMed ID: 24007603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic value of AFP-L3 and PIVKA-II in hepatocellular carcinoma according to total-AFP.
    Choi JY; Jung SW; Kim HY; Kim M; Kim Y; Kim DG; Oh EJ
    World J Gastroenterol; 2013 Jan; 19(3):339-46. PubMed ID: 23372355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Periostin and CA242 as potential diagnostic serum biomarkers complementing CA19.9 in detecting pancreatic cancer.
    Dong D; Jia L; Zhang L; Ma N; Zhang A; Zhou Y; Ren L
    Cancer Sci; 2018 Sep; 109(9):2841-2851. PubMed ID: 29945294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dysbindin as a novel biomarker for pancreatic ductal adenocarcinoma identified by proteomic profiling.
    Guo X; Lv X; Fang C; Lv X; Wang F; Wang D; Zhao J; Ma Y; Xue Y; Bai Q; Yao X; Chen Y
    Int J Cancer; 2016 Oct; 139(8):1821-9. PubMed ID: 27281120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic value of prothrombin induced by the absence of vitamin K or antagonist-II (PIVKA-II) for early stage HBV related hepatocellular carcinoma.
    Wang X; Zhang W; Liu Y; Gong W; Sun P; Kong X; Yang M; Wang Z
    Infect Agent Cancer; 2017; 12():47. PubMed ID: 28852419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD63-positive extracellular vesicles are potential diagnostic biomarkers of pancreatic ductal adenocarcinoma.
    Odaka H; Hiemori K; Shimoda A; Akiyoshi K; Tateno H
    BMC Gastroenterol; 2022 Mar; 22(1):153. PubMed ID: 35350978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The combination of PIVKA-II and AFP improves the detection accuracy for HCC in HBV caucasian cirrhotics on long-term oral therapy.
    Loglio A; Iavarone M; Facchetti F; Di Paolo D; Perbellini R; Lunghi G; Ceriotti F; Galli C; Sandri MT; Viganò M; Sangiovanni A; Colombo M; Lampertico P
    Liver Int; 2020 Aug; 40(8):1987-1996. PubMed ID: 32301212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accuracy of simultaneous measurement of serum biomarkers: Carbohydrate antigen 19-9, pancreatic elastase-1, amylase, and lipase for diagnosing pancreatic ductal adenocarcinoma.
    Yang CY; Lin RT; Chen CY; Yeh CC; Tseng CM; Huang WH; Lee TY; Chu CS; Lin JT
    J Formos Med Assoc; 2022 Dec; 121(12):2601-2607. PubMed ID: 35918272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Usefulness of AFP, AFP-L3, and PIVKA-II, and their combinations in diagnosing hepatocellular carcinoma.
    Park SJ; Jang JY; Jeong SW; Cho YK; Lee SH; Kim SG; Cha SW; Kim YS; Cho YD; Kim HS; Kim BS; Park S; Bang HI
    Medicine (Baltimore); 2017 Mar; 96(11):e5811. PubMed ID: 28296720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High levels of serum glypican-1 indicate poor prognosis in pancreatic ductal adenocarcinoma.
    Zhou CY; Dong YP; Sun X; Sui X; Zhu H; Zhao YQ; Zhang YY; Mason C; Zhu Q; Han SX
    Cancer Med; 2018 Nov; 7(11):5525-5533. PubMed ID: 30358133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of γ-glutamyltransferase-to-albumin ratio in patients with pancreatic ductal adenocarcinoma following radical surgery.
    Li S; Xu H; Wu C; Wang W; Jin W; Gao H; Li H; Zhang S; Xu J; Zhang W; Xu S; Li T; Ni Q; Yu X; Liu L
    Cancer Med; 2019 Feb; 8(2):572-584. PubMed ID: 30632317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Growth differentiation factor (GDF-15) concentration combined with Ca125 levels in serum is superior to commonly used cancer biomarkers in differentiation of pancreatic mass.
    Hogendorf P; Durczyński A; Skulimowski A; Kumor A; Poznańska G; Strzelczyk J
    Cancer Biomark; 2018 Feb; 21(3):505-511. PubMed ID: 29171983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.